Back to Previous Page

IFN-gamma2 (human) LANCE TR-FRET Detection Kit, 500 assay points

ITEM#: 2013-TRF3039C

MFR#: TRF3039C

The LANCE® Ultra Human IFN-lambda2 Detection Kit is designed for detection and quantitation of human interferon lambda2 in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay..The LANCE Ultr

GSA_Logo ECAT_Logo
The LANCE® Ultra Human IFN-lambda2 Detection Kit is designed for detection and quantitation of human interferon lambda2 in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay..The LANCE Ultra Human IFN-lambda2 Detection Kit is designed for detection and quantitation of human interferon lambda2 in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay. No-wash steps, no separation steps TR-FRET technology Sensitive detection High reproducibility Faster time-to-results Easy automation 96-well, 384-well, and 1536-well formats LANCE and LANCE (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm. Interferon-lambda2 (IFN-lambda2), also know an IL28A is a cytokine encoded by the IL28 gene and is closely related to IL28B (IFN-lambda3) and IL29(IFN-lambda1). IFN-lambda2 and IFN-lambda3 are 96% homologous and their functional differences are still unknown. IFN-lambda2 plays a critical role in adaptive immune responses and regulates CD8+ T cell functions during vaccination. Clinically, it is involved in the protection from H1N1 viral infection and it can be used for predicting response to hepatitis C treatment with interferon and ribavirin.